News & PR | alphatau

Alpha Tau Medical

Alpha Tau to Present at Biotech Showcase and Participate in LifeSci Advisors Corporate Access Event

JERUSALEM, December 13, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau," or the “Company”), the developer of the...

Alpha Tau Medical

Alpha Tau Medical Announces Third Quarter 2022 Financial Results and Provides Corporate Update

JERUSALEM, November 22, 2022 - Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the “Company”), the developer of the...

Alpha Tau Medical

Alpha Tau to Present at Upcoming November Investor Conferences

JERUSALEM, November 9, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau", or the “Company”), the developer of the...

Alpha Tau Medical

Alpha Tau Announces Multiple Corporate Updates Ahead of 2022 Annual Meeting of the American Society

- Medicines and Healthcare products Regulatory Agency of the United Kingdom approves clinical trial in squamous cell carcinoma of the...

Alpha Tau Medical

Acceptance in Major Peer-Reviewed Journals of two Landmark Pre-Clinical Studies

Alpha Tau Announces the Acceptance in Major Peer-Reviewed Journals (International Journal of Radiation Oncology, Biology, Physics, and...

Alpha Tau Medical

Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer

JERUSALEM, September 1, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation...

Privacy Policy